Cipla has announced its unaudited consolidated financial results for quarter ended September 30th, 2021.
Key highlights of the quarter
▪One India: Overall business grew by 16% YoY on high FY21 base led by sustained volume traction across core therapies; COVID portfolio contribution normalising in-line with expectations
▪ SAGA: Continued market beating growth in South Africa private business; SAGA grew 8% YoY in USD terms
▪ US business: Reported USD 142Mn revenue at multi-quarter high; Steady momentum in core produ